Mutual Fund Details
NAV
₹532.9219
as on 26 Jul 2024, 11:14 PM
₹9.9373(1.90%)
Last Change
Scheme Ratings
5
Pharma
5Y Returns
3
rated by Value Research
Pharma
Rankings based on 5Y Returns | as on 27 Jul 2024
×
1
DSP Healthcare Fund Direct - Growth
31.39%
2
Mirae Asset Healthcare Fund Direct - Growth
30.34%
3
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
30.21%
4
SBI Healthcare Opportunities Fund Direct Plan-Growth
29.26%
5
Nippon India Pharma Fund Direct-Growth
28.48%
Schemes Managed By
Investment Performance
would have given a return of
₹1,10,871
₹1,21,647
₹1,53,486
₹1,57,698
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
₹57,698
Profit (absolute return)
57.70%
in the last
1m
3m
1y
3y
5y
max
+1% Higher Returns
With Direct Plans on Paytm MoneyInvestment Returns
In the last 3 months
12.76%
In the last 6 months
18.91%
In the last 1 year
46.35%
In the last 3 years
57.70%
In the last 5 years
255.24%
In the last 10 years
429.32%
Absolute Returns
CAGR
Scheme Riskometer
low
low to moderate
moderate
moderately high
high
very high
Investors understand that their principal will be at very high risk
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 30 Jun 2024, 05:30 AM
₹7,404.21 Cr
Scheme Asset Size
Fund Type
Open-End
Exit Load
Exit load of 1% if redeemed within 1 month.
0.92%
Expense Ratio
Plan
Growth
Benchmark
BSE Healthcare Total Return Index
Exit Load
Exit load of 1% if redeemed within 1 month.
Scheme Document
Sectors Holding in this Mutual Fund
as on 30 Jun 2024
Healthcare
99.44%
₹7,362.75 Cr
Others
0.56%
₹41.46 Cr
Companies Holding in this Mutual Fund
as on 30 Jun 2024
Sun Pharmaceutical Industries Ltd.
13.47%
₹997.35 Cr
Divi's Laboratories Ltd.
8.39%
₹621.21 Cr
Lupin Ltd.
7.67%
₹567.90 Cr
Cipla Ltd.
6.20%
₹459.06 Cr
Dr. Reddy's Laboratories Ltd.
6.05%
₹447.95 Cr
Others
58.22%
₹4,310.73 Cr
View All
View All
This fund's returns:
16.38%Return Duration
3 Years
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
12.45%
19.55%
3Y Returns
19.55
DSP Healthcare Fund Direct - Growth
EquityPharma
Min. Investment
₹100
Category Returns
12.45%
19.55%
3Y Returns
18.86
Tata India Pharma & HealthCare Fund Direct-Growth
EquityPharma
Min. Investment
₹100
Category Returns
12.45%
19.55%
3Y Returns
18.52
About Nippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth is a Equity mutual fund scheme from Nippon India Mutual Fund. This scheme was launched on Invalid date and is currently managed by its fund manager Sailesh Raj Bhan. It has an AUM of ₹7,404.21 Crores and the latest NAV decalared is ₹532.922 as on 27 Jul 2024 at 10:49 am.
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 46.35%, in last 3 years is 57.70% and 662.79% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
| AUM: | ₹7,404.21 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
View AMC Details
₹5,13,159.79 Cr
AUM
250
Schemes
Address
4th Floor, Tower A, Peninsula Business Park,Ganapatrao Kadam Marg, Lower Parel (W),400013
Email / Website
Start investing in minutes
Download app to Explore
Scan this QR code to download the app now!
Or download from
